Etafedrine

Etafedrine

SCHEMBL14384530

CCN(C)[C@@H](C)[C@H](O)c1ccccc1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.68
ALDH1A1 P00352 2/20 0.68
AOC3 Q16853 7/20 0.63
GAA P10253 1/20 0.56
SLC6A4 P31645 2/20 0.50
ADRA2C P18825 2/20 0.50
ADRA2A P08913 1/20 0.50
LMNA P02545 1/20 0.50
HIF1A Q16665 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CHRM2 P08172 1/20 0.47
ADRA1A P35348 1/20 0.47
RGS12 O14924 1/20 0.47
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Etafedrine SCHEMBL14643068 1.00 KDM4E (0.68) KDM4EALDH1A1AOC3GAASLC6A4
Etafedrine SCHEMBL249050 1.00 KDM4E (0.68) KDM4EALDH1A1AOC3GAASLC6A4
Etafedrine SCHEMBL123128 0.98 ALDH1A1 (0.66) KDM4EALDH1A1AOC3GAASLC6A4
Etafedrine SCHEMBL1649039 0.96 KDM4E (0.63) KDM4EALDH1A1AOC3GAASLC6A4
SCHEMBL13359192 0.87 KDM4E (0.61) KDM4EALDH1A1AOC3GAASLC6A4
SCHEMBL14024243 0.85 KDM4E (0.63) KDM4EALDH1A1AOC3GAASLC6A4
SCHEMBL11127338 0.85 KDM4E (0.63) KDM4EALDH1A1AOC3GAASLC6A4
SCHEMBL2712000 0.84 KDM4E (0.62) KDM4EALDH1A1AOC3GAASLC6A4
SCHEMBL30062527 0.83 ALDH1A1 (0.61) KDM4EALDH1A1AOC3GAASLC6A4
SCHEMBL22547531 0.82 AOC3 (0.61) KDM4EALDH1A1AOC3GAASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119546288-A Novel lipid-based small molecule integrin receptor-ligand agonist adjuvant carrier compositions, integrin agonist adjuvant pharmaceutical compositions thereof, and methods of making and using the same 7山药物公司 2025-02-28 CN disclosed
US-20080242876-A1 Process For the Manufacture of Substituted Propionic Acids PHOENIX CHEMICALS LTD. (GB) 2008-10-02 US disclosed
WO-2007130429-A2 HISTONE DEACETYLASE AND TUBULIN DEACETYLASE INHIBITORS THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-11-15 WO disclosed
WO-2007095584-A2 Histone Deacetylase Inhibitors THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242876-A1 Process For the Manufacture of Substituted Propionic Acids AS3MT, PPA1, AGPS KDM4E 3119/4885ALDH1A1 14/4885AOC3 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.